Kevin Thomas Ferro

Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

Oikos Holdings LLC is a financial advisory services holding private company. The company is based in New York, NY and has subsidiaries in the United States. The company was founded by Kevin Thomas Ferro.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.

Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.

D. E. Shaw & Co. LP (DESCO) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 1992 by David Elliot Shaw. DESCO serves as the managing member, manager and/or investment advisor of certain entities in the D. E. Shaw Group and provides investment advice to a number of affiliated hedge funds and other entities. The investor base of the funds includes institutional investors and other highly sophisticated, high-net worth participants.